EIF4ENIF1 Antibody (N-term) Blocking Peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | Q9NRA8 |
---|---|
Clone Names | 100517141 |
Gene ID | 56478 |
---|---|
Other Names | Eukaryotic translation initiation factor 4E transporter, 4E-T, eIF4E transporter, Eukaryotic translation initiation factor 4E nuclear import factor 1, EIF4ENIF1 |
Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
Name | EIF4ENIF1 (HGNC:16687) |
---|---|
Function | EIF4E-binding protein that regulates translation and stability of mRNAs in processing bodies (P-bodies) (PubMed:16157702, PubMed:24335285, PubMed:27342281, PubMed:32354837). Plays a key role in P-bodies to coordinate the storage of translationally inactive mRNAs in the cytoplasm and prevent their degradation (PubMed:24335285, PubMed:32354837). Acts as a binding platform for multiple RNA-binding proteins: promotes deadenylation of mRNAs via its interaction with the CCR4-NOT complex, and blocks decapping via interaction with eIF4E (EIF4E and EIF4E2), thereby protecting deadenylated and repressed mRNAs from degradation (PubMed:27342281, PubMed:32354837). Component of a multiprotein complex that sequesters and represses translation of proneurogenic factors during neurogenesis (By similarity). Promotes miRNA-mediated translational repression (PubMed:24335285, PubMed:27342281, PubMed:28487484). Required for the formation of P- bodies (PubMed:16157702, PubMed:22966201, PubMed:27342281, PubMed:32354837). Involved in mRNA translational repression mediated by the miRNA effector TNRC6B by protecting TNRC6B-targeted mRNAs from decapping and subsequent decay (PubMed:32354837). Also acts as a nucleoplasmic shuttling protein, which mediates the nuclear import of EIF4E and DDX6 by a piggy-back mechanism (PubMed:10856257, PubMed:28216671). |
Cellular Location | Cytoplasm, P-body. Cytoplasm. Nucleus. Nucleus, PML body. Nucleus speckle. Note=Predominantly cytoplasmic (PubMed:10856257). Mainly localizes to processing bodies (P-bodies) (PubMed:16157702). Shuttles between the nucleus and the cytoplasm in a CRM1-dependent manner (PubMed:10856257). Localization to nuclear foci and speckles requires active transcription (PubMed:22090346) |
Tissue Location | Widely expressed.. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
The protein encoded by this gene is a nucleocytoplasmicshuttle protein for the translation initiation factor eIF4E. Thisshuttle protein interacts with the importin alpha-beta complex tomediate nuclear import of eIF4E. It is predominantly cytoplasmic;its own nuclear import is regulated by a nuclear localizationsignal and nuclear export signals. Multiple transcript variantsencoding different isoforms have been found for this gene.
References
Suzuki, Y., et al. J. Biol. Chem. 284(51):35597-35604(2009)Venkatesan, K., et al. Nat. Methods 6(1):83-90(2009)Lee, H.C., et al. Biochem. Biophys. Res. Commun. 369(4):1160-1165(2008)Denoeud, F., et al. Genome Res. 17(6):746-759(2007)Lim, J., et al. Cell 125(4):801-814(2006)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.